Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Latest Information Update: 27 Sep 2024
Price :
$35 *
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms Isa-RVD
- 29 Jul 2022 Status changed from not yet recruiting to recruiting.
- 14 Jan 2022 Planned initiation date changed from 15 Dec 2021 to 15 Feb 2022.
- 19 Nov 2021 New trial record